← Back to Search

Communities That HEAL Intervention for Opioid Use Disorder

N/A

Waitlist Available

Research Sponsored by RTI International

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up months 19-30

Awards & highlights

Study Summary

This trial will test a new intervention aimed at reducing opioid overdose deaths by 40% in 67 communities that are highly affected by addiction.

Who is the study for?

The HEALing Communities Study is for communities in Kentucky, Ohio, Massachusetts, or New York that are heavily impacted by opioid overdoses. Eligible communities must have a high rate of opioid-related deaths and be willing to implement strategies like medication-assisted treatment (MOUD), overdose training, and naloxone distribution.Check my eligibility

What is being tested?

This study tests the 'Communities That HEAL' intervention aimed at reducing opioid overdose deaths by 40%. Some communities will start the program right away while others will wait to begin. The effectiveness of this community-wide approach on preventing deaths from opioids is being compared.See study design

What are the potential side effects?

Since this trial involves community interventions rather than medications, there aren't traditional side effects. However, potential challenges could include resistance to change within communities or difficulties in coordinating across different sectors like healthcare and justice.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ months 19-30

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~months 19-30

This trial's timeline: 3 weeks for screening, Varies for treatment, and months 19-30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of opioid overdose deaths

Secondary outcome measures

Opioids

Buprenorphine

Naloxone

Trial Design

2Treatment groups

Experimental Treatment

Group I: Wave 2 - Wait-list comparisonExperimental Treatment1 Intervention

Communities in Wave 2 will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.

Group II: Wave 1 - InterventionExperimental Treatment1 Intervention

Communities in Wave 1 will receive the CTH intervention during the first 30 months of the trial. The intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Boston Medical CenterOTHER

382 Previous Clinical Trials

869,332 Total Patients Enrolled

Columbia UniversityOTHER

1,431 Previous Clinical Trials

2,460,766 Total Patients Enrolled

RTI InternationalLead Sponsor

188 Previous Clinical Trials

875,897 Total Patients Enrolled

Media Library

Communities That HEAL Clinical Trial Eligibility Overview. Trial Name: NCT04111939 — N/A

Opioid Use Disorder Clinical Trial 2023: Communities That HEAL Highlights & Side Effects. Trial Name: NCT04111939 — N/A

Communities That HEAL 2023 Treatment Timeline for Medical Study. Trial Name: NCT04111939 — N/A

Opioid Use Disorder Research Study Groups: Wave 2 - Wait-list comparison, Wave 1 - Intervention

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In how many different locations is this trial being conducted today?

"Patients are being accepted at this trial's many locations, which include Ohio State University, University of Kentucky, and Columbia University."

Answered by AI

Are medical personnel still administering this treatment to test subjects?

"According to the most recent information available on clinicaltrials.gov, this particular study is not presently looking for volunteers. The trial was initially posted on October 23rd, 2019 but was last updated on June 13th, 2020. There are 554 other trials that are currently recruiting patients."

Answered by AI

Who else is applying?

What site did they apply to?

University of Kentucky

What portion of applicants met pre-screening criteria?

Met criteria

How many prior treatments have patients received?

Why did patients apply to this trial?

I have been on some type of drugs for 30 years or so. I would love to get some type, of rime or or reason. I would give anything to put a this behind me.. this could be what I have been waiting for.

PatientReceived 1 prior treatment

Recent research and studies

Drug and Alcohol DependenceJournal

Operationalizing and Selecting Outcome Measures for the Healing Communities Study

Slavova, Svetla, Marc R. LaRochelle, Elisabeth D. Root, Daniel J. Feaster, Jennifer Villani, Charles E. Knott, Jeffery Talbert, et al.. 2020. “Operationalizing and Selecting Outcome Measures for the Healing Communities Study”. Drug and Alcohol Dependence. Elsevier BV. doi:10.1016/j.drugalcdep.2020.108328.

Drug and Alcohol DependenceJournal

Introduction to the Special Issue on the Healing Communities Study

El-Bassel, Nabila, Rebecca D. Jackson, Jeffrey Samet, and Sharon L. Walsh. 2020. “Introduction to the Special Issue on the Healing Communities Study”. Drug and Alcohol Dependence. Elsevier BV. doi:10.1016/j.drugalcdep.2020.108327.

Drug and Alcohol DependenceJournal

Community Dashboards to Support Data-informed Decision-making in the Healing Communities Study

Wu, Elwin, Jennifer Villani, Alissa Davis, Naleef Fareed, Daniel R. Harris, Timothy R. Huerta, Marc R. LaRochelle, Cortney C. Miller, and Emmanuel A. Oga. 2020. “Community Dashboards to Support Data-informed Decision-making in the Healing Communities Study”. Drug and Alcohol Dependence. Elsevier BV. doi:10.1016/j.drugalcdep.2020.108331.

Drug and Alcohol DependenceJournal